DrugPatentWatch Database Preview
Details for Patent: 8,034,809
Email this page to a colleague
See Plans and PricingWhich drugs does patent 8,034,809 protect, and when does it expire?
Patent 8,034,809 protects STIOLTO RESPIMAT and STRIVERDI RESPIMAT and is included in two NDAs.
This patent has twenty-five patent family members in twenty countries.
Summary for Patent: 8,034,809
| Title: | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
| Abstract: | Enantiomerically pure compounds of general formula 1 ##STR00001## wherein the groups R.sup.1, R.sup.2, R.sup.3, R.sup.4, and X.sup.- may have the meanings given in the claims and in the specification, processes for preparing them and the use thereof as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints. |
| Inventor(s): | Lustenberger; Philipp (Basel, CH), Konetzki; Ingo (Warthausen, DE), Sieger; Peter (Mittelbiberach, DE) |
| Assignee: | Boehringer Ingelheim International GmbH (Ingelheim, DE) |
| Application Number: | 12/335,076 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,034,809
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | STIOLTO RESPIMAT | olodaterol hydrochloride; tiotropium bromide | SPRAY, METERED;INHALATION | 206756-001 | May 21, 2015 | RX | Yes | Yes | Start Trial | Start Trial | TREATMENT OF COPD | Start Trial | ||||
| Boehringer Ingelheim | STRIVERDI RESPIMAT | olodaterol hydrochloride | SPRAY, METERED;INHALATION | 203108-001 | Jul 31, 2014 | RX | Yes | Yes | Start Trial | Start Trial | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,034,809
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Germany | 10 2004 024 454 | May 14, 2004 |
International Family Members for US Patent 8,034,809
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2005243469 | Start Trial | |||
| Brazil | PI0511102 | Start Trial | |||
| Canada | 2562859 | Start Trial | |||
| China | 101133039 | Start Trial | |||
| China | 102827097 | Start Trial | |||
| China | 106146425 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
